ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 147 filers reported holding ASCENDIS PHARMA A/S in Q4 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $49,331,000 | -61.7% | 375,000 | -62.5% | 0.20% | -68.6% |
| Q1 2021 | $128,880,000 | -22.7% | 1,000,000 | 0.0% | 0.64% | -36.2% |
| Q4 2020 | $166,780,000 | -13.5% | 1,000,000 | -20.0% | 1.00% | -24.8% |
| Q3 2020 | $192,900,000 | +14.4% | 1,250,000 | +9.6% | 1.33% | -1.1% |
| Q2 2020 | $168,606,000 | +8.8% | 1,140,000 | -17.2% | 1.35% | +1.4% |
| Q1 2020 | $154,991,000 | -12.9% | 1,376,349 | +7.6% | 1.33% | +10.7% |
| Q4 2019 | $177,934,000 | +19.2% | 1,279,000 | -17.5% | 1.20% | +6.5% |
| Q3 2019 | $149,296,000 | -15.8% | 1,550,000 | +0.6% | 1.13% | -2.2% |
| Q2 2019 | $177,331,000 | +0.4% | 1,540,000 | +2.7% | 1.15% | -13.2% |
| Q1 2019 | $176,550,000 | +88.0% | 1,500,000 | +0.0% | 1.33% | +92.7% |
| Q4 2018 | $93,931,000 | -9.0% | 1,499,297 | +2.9% | 0.69% | +13.0% |
| Q3 2018 | $103,264,000 | +6.5% | 1,457,297 | 0.0% | 0.61% | +1.8% |
| Q2 2018 | $96,939,000 | +15.2% | 1,457,297 | +13.2% | 0.60% | +2.7% |
| Q1 2018 | $84,157,000 | – | 1,286,800 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |